Genentech Receives FDA Accelerated Approval for Cancer Treatment

Date : 08/15/2019 @ 8:36PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 38.4  0.005 (0.01%) @ 9:13PM
After Hours
Last Trade
Last $ 38.47 ▲ 0.07 (0.18%)

Genentech Receives FDA Accelerated Approval for Cancer Treatment

Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart

6 Months : From Jun 2019 to Dec 2019

Click Here for more Roche Holding (QX) Charts.
   By Dave Sebastian 

Genentech Inc. received accelerated approval for its Rozlytrek treatment for cancer with the NTRK genetic defect, the U.S. Food and Drug Administration said Thursday.

The treatment has gone through four clinical trials studying adults with tumors caused by the genetic defect, the FDA said. The trials demonstrated the ability to shrink tumors in 57% of patients and to eliminate them in 7.4% of patients.

FDA also approved Rozlytrek for its treatment of adults with non-small cell lung cancer with ROS1-positive tumors and has spread to other parts of the body.

"We're seeing continued advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine," FDA Acting Commissioner Ned Sharpless said in a statement.


Write to Dave Sebastian at


(END) Dow Jones Newswires

August 15, 2019 16:21 ET (20:21 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.